Doctronic Secures $40M Series B as First AI System Legally Authorized to Renew Prescriptions in the U.S.
核心洞察
Doctronic (搜索) raised $40 million in Series B funding co-led by Abstract (搜索) and Lightspeed Venture Partners (搜索), bringing total funding to over $65 million following 15× growth in six months.
The company became the first AI-native platform legally authorized to autonomously renew prescriptions under Utah's regulatory sandbox, handling 190 medications with 24/7 physician escalation protocols.
Doctronic (搜索) now serves over 300,000 weekly users and has achieved 8-figure annualized revenue while maintaining a 99.2% treatment alignment rate in real clinical scenarios.
Doctronic (搜索), the first AI system legally authorized to practice medicine in the United States, announced a $40 million Series B funding round co-led by Abstract (搜索) and Lightspeed Venture Partners (搜索). The financing brings the company's total funding to more than $65 million across three rounds completed in less than 12 months.
The funding follows exceptional growth metrics, with Doctronic (搜索) achieving 15× revenue growth in less than six months since closing its Series A round, reaching 8-figure annualized revenue. The platform now serves more than 300,000 unique weekly visitors while nearly tripling its repeat patient rate during this period.
Regulatory Breakthrough in Utah
In December, Doctronic (搜索) became the first AI-native platform to autonomously renew prescriptions under Utah's AI Learning Lab regulatory sandbox. The program handles 190 medications and operates under strict safety protocols, including automatic 24/7 escalation to licensed physicians for complex cases.
"Doctronic (搜索) proved what we believed from the start: AI can deliver better healthcare outcomes at scale," said Ramtin Naimi, Partner at Abstract (搜索). "The Utah program validated their clinical rigor. The revenue growth validated market demand. What sets them apart is the courage to take responsibility for outcomes—not just provide information."
Clinical Performance and Safety Protocols
The AI system operates its own clinical practice, licensed in all 50 states and HIPAA-compliant. Doctronic (搜索) maintains direct access to patient records via QHIN/TEFCA, medication history through Surescripts, and drug interaction screening through First Databank. The platform has achieved a 99.2% treatment alignment rate in real clinical scenarios.
"Our AI performs dozens of safety checks per prescription renewal that would take a human physician an hour," said Dr. Adam Oskowitz, co-founder of Doctronic (搜索). "The 99.2% treatment alignment rate isn't theoretical, it's from real patients in real clinical scenarios."
Multi-Agent Architecture and Clinical Responsibility
Unlike general-purpose AI assistants that provide health information, Doctronic (搜索) takes responsibility for clinical outcomes through a collective intelligence architecture where multiple specialized AI agents conduct structured clinical reasoning under physician oversight. The company maintains first-of-its-kind AI medical malpractice insurance for cases where the AI practices medicine independently.
Faraz Fatemi, Partner at Lightspeed Venture Partners (搜索), noted: "They've built autonomous AI that integrates safely into real clinical workflows and brings in real patient context—uniquely delivering on the treatment through triage vision at an unmatched scale."
Market Expansion and Partnerships
Doctronic (搜索) serves health systems, payers, and employers through co-branded digital health partnerships while maintaining its direct-to-consumer platform. The company is in active discussions with regulators in other states and governments to expand AI prescription services beyond Utah.
"Health systems see us as infrastructure, the digital front door that routes their patients efficiently and keeps care in-network. Payers see us as unlimited primary care at predictable cost," said Matt Pavelle, co-founder of Doctronic (搜索).
The Series B funding will support expansion into academic medical centers, digital health platforms, and payers, as well as fund expansion into pediatrics where consumer demand significantly outpaces access. The platform provides free AI consultations delivering four potential diagnoses and treatment plans, with licensed physician video visits available for insurance copay or $39.